In early February, Cello Health Consulting’s Carl Engleman moderated a panel discussion with senior biotech leaders at the LSX World...
Considerations around ‘value’ assessment for gene and cell therapies in rare diseases was a theme addressed by several speakers, to close...
Dr. Adrian Bot (VP of Translational Medicine – Kite, a Gilead Company) provides an update on the factors determining durable responses...
As a passionate advocate for gene and cell therapies, Fiona Thistlethwaite (Medical Oncology Consultant at The Christie Hospital &...
Really insightful talk delivered by Dr. Mythill Koneru (Chief Medical Officer – Marker Therapeutics) @ the CAR-TCR Summit Europe 2020
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net
